Page 42 - CPG endometrial cancer
P. 42
ผศ.นพ.ศภุ วฒั น์ เลาหวิริยะกมล
14. Meijers-Heijboer H, van Geel B, van Putten Project ( NSABP- P1) Breast Cancer Prevention
WL, et al. Breast cancer after prophylactic Trial. JAMA 2001;286:2251-6.
bilateral mastectomy in women with a BRCA1 or 21. Fisher B, Costantino JP, Wickerham DL, et al.:
BRCA2 mutation. N Engl J Med 2001;345:159-64. Tamoxifen for prevention of breast cancer: report of
15. Carbine NE, Lostumbo L, Wallace J, Ko H. the National Surgical Adjuvant Breast and Bowel
Risk-reducing mastectomy for the prevention of Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
primary breast cancer. Cochrane Database 22. Ingle JN, Liu M, Wickerham DL, et al. Selective
Syst Rev 2018;4:CD002748. estrogen receptor modulators and pharmacogenomic
16. Jakub JW, Peled AW, Gray RJ, et al. Oncologic variation in ZNF423 regulation of BRCA1 expression:
safety of prophylactic nipple-sparing mastectomy individualized breast cancer prevention. Cancer
in a population with BRCA mutations: a multi- Discov 2013;3:812-25.
institutional study. JAMA Surg 2018;153:123-9. 23. Nemati Shafaee M, Gutierrez-Barrera AM,
17. Yao K, Liederbach E, Tang R, et al.: Nipple- Lin HY, et al. Aromatase inhibitors and the
sparing mastectomy in BRCA1/ 2 mutation risk of contralateral breast cancer in BRCA
carriers: an interim analysis and review of the mutation carriers. J Clin Oncol 2015;33:31-3.
literature. Ann Surg Oncol 2015;22:370-6. 24. Narod SA, Dube MP, Klijn J, et al. Oral
18. Manning AT, Wood C, Eaton A, et al. : contraceptives and the risk of breast cancer
Nipple- sparing mastectomy in patients with in BRCA1 and BRCA2 mutation carriers. J Natl
BRCA1/2 mutations and variants of uncertain Cancer Inst 2002;94:1773-9.
significance. Br J Surg 2015;102:1354-9. 25. Haile RW, Thomas DC, McGuire V, et al. BRCA1
19. Cuzick J, Sestak I, Bonanni B, et al. Selective and BRCA2 mutation carriers, oral contraceptive
oestrogen receptor modulators in prevention of use, and breast cancer before age 50. Cancer
breast cancer: an updated meta-analysis of individual Epidemiol Biomarkers Prev 2006;15:1863-70.
participant data. Lancet 2013;381:1827-34. 26. Moorman PG, Havrilesky LJ, Gierisch JM, et al.
20. King MC, Wieand S, Hale K, et al. Tamoxifen Oral contraceptives and risk of ovarian cancer and
and breast cancer incidence among women with breast cancer among high-risk women: a systematic
inherited mutations in BRCA1 and BRCA2: reviewandmeta-analysis.JClinOncol 2013;31:4188-98.
National Surgical Adjuvant Breast and Bowel
33
